Home Cart Sign in  
Chemical Structure| 1616493-44-7 Chemical Structure| 1616493-44-7

Structure of Tucidinostat
CAS No.: 1616493-44-7

Chemical Structure| 1616493-44-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tucidinostat is an inhibitor of HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor with IC50s of 95, 160, 67 and 78 nM, espectively.

Synonyms: Chidamide; HBI-8000; CS 055

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tucidinostat

CAS No. :1616493-44-7
Formula : C22H19FN4O2
M.W : 390.41
SMILES Code : O=C(NC1=CC=C(F)C=C1N)C2=CC=C(CNC(/C=C/C3=CC=CN=C3)=O)C=C2
Synonyms :
Chidamide; HBI-8000; CS 055
MDL No. :MFCD28100259
InChI Key :SZMJVTADHFNAIS-BJMVGYQFSA-N
Pubchem ID :12136798

Safety of Tucidinostat

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Tucidinostat

epigenetics

Isoform Comparison

Biological Activity

Target
  • HDAC10

    HDAC10, IC50:78 nM

  • HDAC3

    HDAC3, IC50:67 nM

  • HDAC2

    HDAC2, IC50:160 nM

  • HDAC1

    HDAC1, IC50:95 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
4T1 breast cancer cells 2.5, 5, 7.5 μM 24 hours To assess the effect of Tucidinostat on cell proliferation, results showed significant suppression of cell proliferation PMC9648046
LLC lung cancer cells 2.5, 5, 7.5 μM 24 hours To assess the effect of Tucidinostat on cell proliferation, results showed significant suppression of cell proliferation PMC9648046
CT26 colorectal cancer cells 2.5, 5, 7.5 μM 24 hours To assess the effect of Tucidinostat on cell proliferation, results showed significant suppression of cell proliferation PMC9648046
Raw 264.7 cells 2.5, 5, 7.5 μM 24 hours To assess the effect of Tucidinostat on M1 polarization of macrophages, results showed increased expression of M1 markers iNOS and CD86 PMC9648046
bone marrow-derived macrophages (BMDMs) 2.5, 5, 7.5 μM 24 hours To assess the effect of Tucidinostat on M1 polarization of macrophages, results showed increased expression of M1 markers iNOS and CD86 PMC9648046
MV411 cells 0, 0.25, 0.5 and 1.0 μM 48 hours Evaluate the antiproliferative activity of Tucidinostat, results showed that the IC50 value of Tucidinostat on MV411 cells was 2.00 ±0.15 mM. PMC10951978
SK-UT-1 1–25 µM 48 hours Tucidinostat inhibited the proliferation of SK-UT-1 cells in a dose-dependent manner. PMC9735512
MES-SA 1–25 µM 48 hours Tucidinostat inhibited the proliferation of MES-SA cells in a dose-dependent manner. PMC9735512
K562 cells 1 µM 72 hours To evaluate the effect of Tucidinostat on K562 cells, the results showed that Tucidinostat treatment significantly altered Dox-btn1 binding events, mainly enhancing binding events and creating new binding sites. PMC10497411

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c or C57 BL/6 mice CT26 colorectal cancer model Oral gavage 12.5, 25, 75 mg/kg daily, for 10 days To assess the effect of Tucidinostat on tumor growth and immune microenvironment, results showed that 25 mg/kg dose significantly inhibited tumor growth and promoted CD8+ T cell infiltration PMC9648046

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02718066 Melanoma Rena... More >>l Cell Carcinoma Non-Small Cell Lung Cancer Less << Phase 1 Phase 2 Recruiting January 2020 United States, Arizona ... More >> [Site 02] Mayo Clinic Arizona Recruiting Phoenix, Arizona, United States, 85054 Contact: Thai Ho          United States, California [Site 11] University of California, San Diego Medical Center Recruiting La Jolla, California, United States, 92037 Contact: Lyudmila Bazhenova          United States, Florida [Site 01] Hematology - Oncology Associates of the Treasure Coast Recruiting Port Saint Lucie, Florida, United States, 34952 Contact: Heather Yeckes-Rodin          [Site 09] H. Lee Moffitt Cancer Center and Research Institute, Inc. Recruiting Tampa, Florida, United States, 33612 Contact: Nikhil Khushalani          United States, Maryland [Site 13] Frederick Memorial Hospital d/b/a James M Stockman Cancer Institute Recruiting Frederick, Maryland, United States, 21702 Contact: Elhamy Eskander          United States, Texas [Site 12] University of Texas M.D. Anderson Cancer Center - Investigational Cancer Therapeutics Recruiting Houston, Texas, United States, 77030 Contact: Siqing Fu Less <<
NCT03574402 Carcinoma, Non-Small-Cell Lung Phase 2 Not yet recruiting December 30, 2024 -
NCT02697552 Non-Hodgkin's Lymphoma PHASE1 COMPLETED 2025-10-16 Nagoya City University Hospita... More >>l, Aichi, Japan|Fukuoka University Hospital, Fukuoka, Japan|NHO Kyushu Cancer Center, Fukuoka, Japan|Kagoshima University Medical and Dental Hospital, Kagoshima, Japan|Tokai University Hospital, Kanagawa, Japan|NHO Kumamoto Medical Center, Kumamoto, Japan|NHO Nagasaki Medical Center, Nagasaki, Japan|National Cancer Center Hospital, Tokyo, Japan Less <<
NCT03605056 Multiple Myeloma Phase 2 Not yet recruiting July 31, 2022 China, Shanghai ... More >> 180 Fenglin Road Active, not recruiting Shanghai, Shanghai, China, 200032 Less <<
NCT03617432 Experimental Tumor Phase 2 Recruiting September 30, 2022 China ... More >> Beijing Cancer Hospital Recruiting Beijing, China, 100142 Contact: Jun Zhu, MD    +86-10-88196596    zj@bjcancer.org    Contact: Weiping Liu, MD    +86-10-88196109    dreaming2217@126.com    Principal Investigator: Jun Zhu, MD Less <<
NCT03602131 Hodgkin Lymphoma ... More >> Non-hodgkin Lymphoma Less << Phase 2 Not yet recruiting March 30, 2021 -
NCT03321890 Peripheral T-cell Lymphoma Phase 2 Recruiting December 31, 2020 China, Guangdong ... More >> Department of Medical Oncology,Sun Yat-Sen University Cancer Center Recruiting Guangzhou, Guangdong, China, 510060 Contact: Zhiming Li, DM    +86-13719189172    Lizhm@sysucc.org.cn    Contact: Yu Wang, DM    86-20-87343765    Wangyu@sysucc.org.cn Less <<
NCT03151876 Lymphoma Phase 2 Recruiting December 2021 China, Beijing ... More >> Beijing cancer hospital Not yet recruiting Beijing, Beijing, China, 100142 Contact: Yan Xie, MD          Peking university third hospital Not yet recruiting Beijing, Beijing, China, 100191 Contact: Xiaoyan Ke, MD          China, Chongqing The first affiliated hospital of Chongqing medical university Not yet recruiting Chongqing, Chongqing, China, 400016 Contact: Lin Liu, MD          Southwest Hospital Recruiting Chongqing, Chongqing, China, 400038 Contact: Dabing Qin, MD          China, Gansu General Hospital of Lanzhou military command Not yet recruiting Lanzhou, Gansu, China, 730070 Contact: Hai Bai, MD          China, Henan Henan cancer hospital Not yet recruiting Zhengzhou, Henan, China, 450008 Contact: Jian Zhou, MD          The first affiliated hospital of Zhengzhou university Not yet recruiting Zhengzhou, Henan, China, 450052 Contact: Xinhua Wang, MD          China, Hubei Tongji Hospital Not yet recruiting Wuhan, Hubei, China, 430030 Contact: Yang Cao, MD          China, Jiangsu Jiangsu province hospital Not yet recruiting Nanjing, Jiangsu, China, 210029 Contact: Wei Xu, MD          China, Shanghai Rui jin hospital Shanghai jiao tong University Not yet recruiting Shanghai, Shanghai, China, 200025 Contact: Jiong Hu, MD          Tong Ren Hospital Not yet recruiting Shanghai, Shanghai, China Contact: Ligen L i u, MD          China, Shanxi Shan Xi Da Yi Hospital Not yet recruiting Taiyuan, Shanxi, China, 030032 Contact: Rong Gong, MD          Tangdu Hospital Not yet recruiting Xi'an, Shanxi, China, 710038 Contact: Qiang Liu, MD          China, Sichuan West China Hospital of Sichuan University Recruiting Chengdu, Sichuan, China, 610044 Contact: Jie Ji, MD    86-28-85422370    jieji@scu.edu.cn    Affiliated Hospital of Southwest Medical University Recruiting Nanchong, Sichuan, China, 646000 Contact: Xiaoming Li, MD          China, Tianjing Blood diseases hospital, Chinese academy of medica Not yet recruiting Tianjin, Tianjing, China, 300020 Contact: Lvgui Qiu, MD          China, Xinjiang The first affiliated hospital of Xinjiang medical Universtiy Not yet recruiting Ürümqi, Xinjiang, China, 830054 Contact: Ming Jiang, MD          China, Yunnan Kunming General Hospital of Chengdu Military Area Not yet recruiting Kunming, Yunnan, China, 650032 Contact: Sanbin Wang, MD Less <<
NCT03564704 Leukemia Leuk... More >>emia, Acute Adult Lymphoblastic Lymphoma Leukemia, Lymphoblastic Leukemia, T Cell Adult Acute Lymphoblastic Leukemia Lymphoblastic Lymphoma Lymphoblastic Leukemia Less << Phase 2 Phase 3 Recruiting May 30, 2021 China, Guangdong ... More >> Department of Hematology, Nanfang Hospital Recruiting Guangzhou, Guangdong, China, 510515 Contact: Hongsheng Zhou    +862062787349    zhs1@i.smu.edu.cn Less <<
NCT03629873 Lymphoma, Large B-Cell, Diffus... More >>e|Mantle Cell Lymphoma|Peripheral T Cell Lymphoma|Double-hit Lymphoma Less << PHASE2 UNKNOWN 2021-12-31 Hematological Department, Peop... More >>le's Hospital of Jiangsu Province, Nanjing, Jiangsu, 210029, China Less <<
NCT02879526 Relapse/Refratory Peripheral T... More >> Cell Lymphoma Less << Phase 2 Recruiting August 2019 China, Jiangsu ... More >> HuaiAn First People's Hospital Recruiting HuaiAn, Jiangsu, China, 223300 Contact: Liang Yu, M.D., Ph.D.          WuXi People's Hospital Recruiting WuXi, Jiangsu, China, 214023 Contact: Yun Zhuang, M.D.          Contact: YunFeng Shen, M.D., Ph.D Less <<
NCT03023358 Peripheral T Cell Lymphoma Phase 3 Not yet recruiting March 2019 China, Guangdong ... More >> Ru Feng Not yet recruiting Guangzhou, Guangdong, China, 510515 Contact: Ru Feng, M.D.    +86 13725119762    ruth1626@hotmail.com    Contact: Qi Wei, M.D.    +86 13427564102    sinbad37@126.com    Principal Investigator: Ru Feng, M.D. Less <<
NCT03553238 Leukemia, Acute ... More >> Leukemia, T Cell Leukemia, Lymphoblastic Less << Phase 2 Phase 3 Recruiting August 30, 2020 China, Guangdong ... More >> Nanfang Hospital, Southern Medical University Recruiting Guangzhou, Guangdong, China, 510515 Contact: Hongsheng Zhou, MD, PhD    +862062787349    zhs1@i.smu.edu.cn Less <<
NCT03453255 Chemotherapy Phase 1 Phase 2 Recruiting December 31, 2020 China ... More >> Chinese PLA General Hospital Recruiting Beijing, China, 100853 Contact: Li Yu, M.D. Ph.D.    86-010-55499003    chunhuiliyu@yahoo.com    Principal Investigator: Li Yu, M.D. Ph.D. Less <<
NCT02753647 Diffuse Large B-cell Lymphoma Phase 2 Recruiting April 2019 China, Shanghai ... More >> Shanghai Ruijin Hospital Recruiting Shanghai, Shanghai, China, 200023 Contact: Weili Zhao, MD,PhD    64370045 ext 610707    zhao.weili@yahoo.com    Contact: Pengpeng Xu, MD    64370045 ext 610707    xpproc@msn.com Less <<
NCT02809573 Peripheral T-cell Lymphoma Phase 1 Recruiting December 2019 China, Beijing ... More >> Cancer Hospital, Chinese Academy of Medical Sciences Recruiting Beijing, Beijing, China, 100000 Contact: Yuankai Shi, MD    +86-10-8778-8293    syuankai@cicams.ac.cn Less <<
NCT03564470 Leukemia Leuk... More >>emia, Acute Leukemia, Lymphoblastic Leukemia, B-cell Less << Phase 2 Phase 3 Recruiting August 30, 2020 China, Guangdong ... More >> Department of Hematology, Nanfang Hospital Recruiting Guangzhou, Guangdong, China, 510515 Contact: Hongsheng Zhou, PhD, MD    86-20-62787349    zhs1@i.smu.edu.cn Less <<
NCT02733380 Diffuse Large B-cell Lymphoma Phase 2 Recruiting May 2020 China, Henan ... More >> Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university Recruiting ZhengZhou, Henan, China, 450008 Contact: Yanyan Liu, M.D.    +8613838176375    yyliu@zzu.edu.cn    Contact: Jiuyang Zhang, Master    +8615003810435    zhangjiuyang9103@163.com    Principal Investigator: Yanyan Liu, M.D. Less <<
NCT01836679 Non-small-cell Lung Cancer Phase 2 Completed - China, Beijing ... More >> Cancer Hospital, Chinese Academy of Medical Sciences Beijing, Beijing, China, 100021 Beijing Chest Hospital, Capital Medical University Beijing, Beijing, China, 101149 China, Hebei Hebei Provincial Tumor Hospital Shijiazhuang, Hebei, China, 050011 China, Jiangsu Jiangsu Cancer Hospital Nanjing, Jiangsu, China, 210009 China, Liaoning The first Hospital of China Medical University Shenyang, Liaoning, China, 110001 China, Shanghai Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University Shanghai, Shanghai, China, 200030 China, Sichuan The Second People's Hospital of Sichuan Chengdu, Sichuan, China, 82816 China, Tianjin Tianjin Medical University Cancer Institute & Hospital Tianjin, Tianjin, China, 300060 Less <<
NCT02987244 T Cell Non-Hodgkin's Lymphoma Phase 1 Phase 2 Recruiting March 2023 China, Beijing ... More >> Peking Union medical college hospital Recruiting Beijing, Beijing, China, 100730 Contact: Wei Zhang          China, Tianjin Tianjin medical universty cancer institute & hospital Recruiting Tianjin, Tianjin, China, 300060 Less <<
NCT02886559 AML Relapse Phase 1 Phase 2 Recruiting June 2019 China ... More >> China PLA General Hospital Recruiting Beijing, China, 100039 Contact: Li Yu, M.D Ph.D    010-66937644    chunhuiliyu@yahoo.com    Principal Investigator: Li-Xin Yu Less <<
NCT03630731 Natural Killer/T-Cell Lymphoma... More >>, Nasal and Nasal-Type Less << Phase 2 Recruiting March 2020 China, Beijing ... More >> Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) Recruiting Beijing, Beijing, China, 100021 Contact: Mei Dong    (86)13811929322    dongmei030224@163.com Less <<
NCT03598959 Extranodal NK/T-cell Lymphoma Phase 2 Not yet recruiting December 31, 2021 China, Sichuan ... More >> West China Hospital of Sichuan University Chengdu, Sichuan, China, 610044 Less <<
NCT03336632 Leukemia, Acute ... More >> MDS Less << Phase 2 Not yet recruiting March 30, 2021 China, Sichuan ... More >> West China Hospital of Sichuan University Chengdu, Sichuan, China, 610044 West China Hospital of Sichuan University Not yet recruiting Chengdu, Sichuan, China, 610044 Contact: Jie Ji, MD    86-28-85422370    jieji@scu.edu.cn Less <<
NCT03273452 Angioimmunoblastic T-cell Lymp... More >>homa Less << PHASE2 UNKNOWN 2025-05-19 The Affiliated Hospital of Qin... More >>gdao University, Qingdao, Shandong, 266000, China Less <<
NCT03611231 Experimental Tumor PHASE2 UNKNOWN 2022-12-30 Beijing, Beijing, Beijing, 100... More >>000, China Less <<
NCT02753543 Peripheral T Cell Lymphoma PHASE2 UNKNOWN 2025-11-19 Ruijin Hospital, Shanghai, Sha... More >>nghai, 200023, China Less <<
NCT03031262 AML Phase 1 Phase 2 Recruiting December 2022 China, Tianjin ... More >> Institute of Hematology & Blood Diseases Hospital Recruiting Tianjin, Tianjin, China Contact: lijun Liu    86-22-23909237    bloodgcp@126.com Less <<
NCT03245905 Relapsed or Refractory B-cell ... More >>Non-Hodgkin's Lymphoma (NHL) Less << PHASE2 UNKNOWN 2021-12-31 Department of Medical Oncology... More >>, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, 510060, China Less <<
NCT03201471 Diffuse Large B Cell Lymphoma Phase 2 Recruiting February 5, 2020 China, Zhejiang ... More >> The first affiliated hospital of Zhejiang University Recruiting Hangzhou, Zhejiang, China, 310000 Contact: Wenbin Qian, MD. PhD.    (+86)13605801032 Less <<
NCT02902185 Chronic HIV Infections Phase 2 Phase 3 Active, not recruiting December 2018 China, Guangxi ... More >> The First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi, China China, Shaanxi Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University Xi'an, Shaanxi, China, 710038 China, Zhejiang Zhejiang University Hangzhou, Zhejiang, China Less <<
NCT03494634 Experimental Tumor PHASE2 UNKNOWN 2020-09-30 Cancer Center of Sun Yat-Sen U... More >>niversity (CCSU), Guangzhou, Guangdong, China Less <<
NCT02482753 Breast Cancer Phase 3 Active, not recruiting March 2019 China, Beijing ... More >> The 307th Hospital of Chinese people's Liberation Army Beijing, Beijing, China, 100021 Less <<
NCT02883374 Adenocystic Carcinoma PHASE2 UNKNOWN 2025-06-20 Cancer Hospital, Chinese Acade... More >>my of Medical Science, Beijing, Beijing, 100021, China Less <<
NCT03268889 Peripheral T Cell Lymphoma UNKNOWN 2020-09-15 the First Affiliated Hospital ... More >>of Soochow University, Suzhou, Jiangsu, 215006, China Less <<
NCT03410004 Experimental PHASE2 UNKNOWN 2020-09-30 -
NCT02856997 Peripheral T Cell Lymphoma Phase 2 Not yet recruiting - -
NCT02815007 Advanced EGFR-TKI-resistant No... More >>n-Small Cell Lung Cancer Less << Phase 2 Unknown June 2018 -
NCT03105596 B-cell Non-Hodgkin's Lymphoma Phase 2 Not yet recruiting September 30, 2019 -
NCT03639168 Adenoid Cystic Carcinomas ... More >> Chidamide Cisplatin Less << Phase 2 Recruiting June 1, 2020 China, Shanghai ... More >> Kai Xue Recruiting Shanghai, Shanghai, China, 200032 Contact: Kai Xue, MD    13818659448    xuekaishanghai@126.com Less <<
NCT02878278 Lymphoma, Extranodal NK-T-Cell... More >> EBV Less << Phase 2 Not yet recruiting September 2019 -
NCT03373019 Chidamide Lym... More >>phoma, B-Cell Lymphoma, Large B-Cell, Diffuse Neoplasm by Histology Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin Cyclophosphamide Rituximab Gemcitabine Cisplatin Dexamethasone HDAC Inhibitor Less << Phase 2 Recruiting March 1, 2021 China, Shanghai ... More >> Kai Xue Recruiting Shanghai, Shanghai, China, 200032 Contact: Kai Xue, MD    13818659448    xuekaishanghai@126.com    China Kai Xue Recruiting Shanghai, China Contact: Kai Xue, MD    13818659448    xuekaishanghai@126.com    Contact: Junning Cao, MD    13818659448 Less <<
NCT02944812 Peripheral T Cell Lymphoma PHASE2 UNKNOWN 2025-01-19 Guangdong general hospital, Gu... More >>angzhou, Guangdong, 510080, China Less <<
NCT02513901 Chronic HIV Infections PHASE1|PHASE2 COMPLETED 2025-02-16 Department of Infectious Disea... More >>ses, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, 710038, China Less <<
NCT05833724 Relapsed or Refractory Periphe... More >>ral T-cell Lymphoma Less << PHASE2 RECRUITING 2025-12-25 Chang Gung Memorial Hospital, ... More >>Kaohsiung, Kaohsiung, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan Less <<
NCT05682755 Leukemia, Myeloid, Acute PHASE1|PHASE2 RECRUITING 2026-12-31 West China Hospital of Sichuan... More >> University, Chengdu, Sichuan, 610044, China Less <<
NCT05890287 HR Positive HER2 Negative Adva... More >>nced Breast Cancer Less << RECRUITING 2026-10-01 天津市肿瘤医院, Tianjin, China
NCT05140616 Safety and Efficacy PHASE1|PHASE2 UNKNOWN 2024-05-31 First Affiliated Hospital,Sooc... More >>how University, Suzhou, Jiangsu, 215000, China Less <<
NCT05991973 T Lymphoblastic Leukemia/Lymph... More >>oma Less << PHASE2 RECRUITING 2025-07-27 The First Hospital of Zhejiang... More >> Medical Colleage Zhejiang University, Hangzhou, Zhejiang, 310006, China Less <<
NCT04511351 Lymphoma UNKNOWN 2020-12-30 National Cancer Center, Cancer... More >> Hospital, Chinese Academy of Medical Scienses, Beijing, Beijing, 100021, China Less <<
NCT02953652 Peripheral T-Cell Lymphoma (PT... More >>CL) Less << PHASE2 COMPLETED 2022-02-17 Akita, Japan|Bunkyōku, Japan|C... More >>hūōku, Japan|Fukuoka, Japan|Isehara, Japan|Kagoshima, Japan|Kobe, Japan|Kotoku, Japan|Kumamoto, Japan|Kyoto, Japan|Maebashi, Japan|Nagoya, Japan|Okayama, Japan|Osakasayama, Japan|Sapporo, Japan|Suita, Japan|Yamagata, Japan|ōmura, Japan|Busan, Korea, Republic of|Goyang-si, Korea, Republic of|Incheon, Korea, Republic of|Seongnam-si, Korea, Republic of|Seoul, Korea, Republic of Less <<
NCT04562311 Bladder Cancer Stage IV PHASE2 ACTIVE_NOT_RECRUITING 2025-10-30 Cancer Center, Sun Yat-sen Uni... More >>versity, Guangzhou, Guangdong, 510060, China Less <<
NCT05747313 Breast Cancer|Chemotherapy Eff... More >>ect Less << PHASE1|PHASE2 UNKNOWN 2023-12-31 National Cancer Center/Nationa... More >>l Clinical Research Center for Cancer/Cancer Hospital, Beijing, Beijing, 00, China Less <<
NCT06550336 Peripheral T Cell Lymphoma PHASE2 ACTIVE_NOT_RECRUITING 2027-12-30 The First Bethune Hospital of ... More >>Jilin University, Changchun, Jilin, 130021, China Less <<
NCT02955589 Adult T-Cell Lymphoma (ATL) PHASE2 COMPLETED 2025-11-19 Fukuoka, Japan|Isehara, Japan|... More >>Kagoshima, Japan|Miyagi, Japan|Miyazaki, Japan|Nagasaki, Japan|Nagoya, Japan|Oita, Japan|Okinawa, Japan|Omura, Japan|Saitama, Japan|Sapporo, Japan|Suita, Japan|Tokyo, Japan|Yufu, Japan Less <<
NCT05276713 Breast Cancer UNKNOWN 2022-08-01 The Fifth Medical Center of PL... More >>A General Hospital, Beijing, Beijing, 100071, China Less <<
NCT04661943 Diffuse Large B-cell Lymphoma PHASE2 UNKNOWN 2022-11-30 The First Bethune Hospital of ... More >>Jilin University, Changchun, Jilin, 130021, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.56mL

0.51mL

0.26mL

12.81mL

2.56mL

1.28mL

25.61mL

5.12mL

2.56mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories